Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  idelalisib
Find trials that include:  Any drugs shown
Results 1-9 of 9 for your search:
Start Over
Dose Optimization Study of Idelalisib in Follicular Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-313-1580, NCI-2015-01816, 2015-000366-66, NCT02536300
Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-312-1579, NCI-2015-01964, NCT02538614
Idelalisib and Ofatumumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-309, NCI-2014-01554, IN-US-312-1237, NCT02135133
Idelalisib in Treating Patients with Relapsed or Refractory Waldenstrom Macroglobulinemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-040, NCI-2015-01605, NCT02439138
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBCL201X2102C, NCI-2016-00163, NCT02603445
Ricolinostat and Ibrutinib or Idelalisib in Treating Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-558, NCI-2016-01352, NCT02787369
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-312-1325, NCI-2014-01500, 2013-005343-82, NCT02136511
Start Over